Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions

Hardman & Co Research on Shield Therapeutics (STX):

Reassuring 1Q’23 Accrufer prescriptions

Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, with the aim of generating prescription (Rx) growth and sales traction. Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23, following recruitment and training of the expanded Shield-Viatris commercial team. In the event that the US goals are achieved, there would be considerable upside potential to the valuation.

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/reassuring-1q23-accrufer-prescriptions/

If you are interested in meeting the company, you can register your interest by clicking on the above link

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.